Rocket Pharmaceuticals Valuation
| RCKT Stock | USD 8.43 0.11 1.32% |
At this time, the company appears to be undervalued. Rocket Pharmaceuticals holds a recent Real Value of $16.9 per share. The prevailing price of the company is $8.43. Our model determines the value of Rocket Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of -0.54, shares outstanding of 106.63 M, and Shares Owned By Institutions of 96.99 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rocket Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Rocket Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Rocket Pharmaceuticals is based on 3 months time horizon. Increasing Rocket Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Rocket Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 8.43, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.43 | Real 16.9 | Target 43.13 | Hype 8.39 | Naive 9.3 |
The intrinsic value of Rocket Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rocket Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rocket Pharmaceuticals helps investors to forecast how Rocket stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rocket Pharmaceuticals more accurately as focusing exclusively on Rocket Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Rocket Pharmaceuticals' intrinsic value based on its ongoing forecasts of Rocket Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Rocket Pharmaceuticals' closest peers.
Rocket Pharmaceuticals Cash |
|
Rocket Valuation Trend
Rocket Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Rocket Pharmaceuticals' financial worth over time. Using both Rocket Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Rocket Pharmaceuticals Total Value Analysis
Rocket Pharmaceuticals is at this time forecasted to have valuation of 552.05 M with market capitalization of 898.89 M, debt of 25.5 M, and cash on hands of 321.37 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rocket Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
552.05 M | 898.89 M | 25.5 M | 321.37 M |
Rocket Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Rocket is to check how much profit was generated for every dollar of assets it reports. Rocket Pharmaceuticals holds a negative application of assets of -0.31 pct., losing $0.003122 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Rocket Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Rocket Pharmaceuticals Ownership Allocation
The majority of Rocket Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rocket Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rocket Pharmaceuticals. Please pay attention to any change in the institutional holdings of Rocket Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Rocket Pharmaceuticals Profitability Analysis
Net Loss for the year was (258.75 M) with profit before overhead, payroll, taxes, and interest of 0.About Rocket Pharmaceuticals Valuation
The stock valuation mechanism determines Rocket Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Rocket Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rocket Pharmaceuticals. We calculate exposure to Rocket Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rocket Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -6.4 M | -6.1 M |
Rocket Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Rocket Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 94.8 M |
Rocket Pharmaceuticals Current Valuation Indicators
Rocket Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Rocket Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rocket Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rocket Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rocket Pharmaceuticals' worth.Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.